Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[3] Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus, but was discontinued due to lack of efficacy
Surg., 187, 383-408, 1978
Ban K, Kim KH, Cho CK, Sauv M, Diamandis EP, Backx PH, Drucker DJ, Husain M: Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
addresses the desire and motivational component rather than the vascular component
Appetite and weight changes are among the most noticeable effects after stopping GLP-1 therapy
The primary outcome was the incremental cost-effectiveness ratio (ICER), defined as cost per QALY gained, with the willingness-to-pay threshold set at AU$28,000 per QALY [15]
US$ 27.68
US$ 29.65
US$ 27.44
US$ 27.18
US$ 28.81
US$ 26.28
US$ 25.88
